iSono Health, a company focused on advancing breast cancer detection, has secured $14.7 million in new investment capital. This funding round will support the company's mission to empower women and their physicians with innovative tools for early detection and monitoring of breast health. The capital infusion marks a significant step in the company's development and market strategy.
The company has developed an AI-driven platform featuring the world’s first automated, portable, and wearable ultrasound device. This patented compact scanner captures 3D quantitative ultrasound images, automatically scanning the entire breast volume in just two minutes per breast. A key advantage of the technology is its ability to capture images without requiring a skilled sonographer, making it accessible for broader use. The device connects to a laptop, transferring data to a secure cloud for processing and storage, allowing radiologists to view images remotely. Its machine-learning algorithm utilizes acoustic biomarkers to identify abnormal masses, enhancing diagnostic capabilities.
iSono Health's platform expands ultrasound use in point-of-care diagnostics and monitoring across various healthcare settings, including radiology centers, walk-in clinics, and mobile units. The system offers several benefits to women and healthcare providers, including no radiation exposure, a pain-free and fast experience, and actionable feedback powered by AI. This investment underscores confidence in iSono Health's technology and its potential to transform breast health management.
The newly raised capital is earmarked to accelerate product development, scale manufacturing, and expand market reach for its innovative breast imaging solution. iSono Health plans to use these funds to further its growth initiatives, aiming to make its accessible and efficient breast cancer detection technology available to a wider population and improve patient outcomes globally.
.png&w=3840&q=75)
